LENZ Therapeutics, Inc.
LENZNASDAQHealthcare● Active
$6.73
$-0.29(-4.07%)
Market Cap$210858300
P/E Ratio—
52W High$50.4
52W Low$6.61
LENZ Therapeutics, Inc. (LENZ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LENZ · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$1.32
Est. -$1.10 · -20.0%
Revenue
$0.00B
Est. $0.00B · +8.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
LENZ reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | -$1.07 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$1.10 | -$1.32 | -20.0% | $0.00B | $0.00B | +8.1% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -$0.91 | -$1.16 | -27.5% | $0.00B | $0.00B | -48.5% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.67 | -$0.59 | +11.9% | $0.01B | $0.00B | +309.9% |
| ▲ Q3 FY2025 | Jul 30, 2025 | -$0.58 | -$0.53 | +8.6% | $0.01B | $0.00B | +600.0% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.55 | -$0.53 | +3.6% | — | — | — |
| ▼ Q1 FY2025 | Mar 19, 2025 | -$0.42 | -$0.46 | -9.5% | — | — | — |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.47 | -$0.38 | +19.1% | — | — | — |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
-$1.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$1.32
EPS Est.
-$1.10
EPS Surpr.
-20.0%
Revenue
$0.00B
Q1 FY2026
Mar 24, 2026Miss
EPS Actual
-$1.16
EPS Est.
-$0.91
EPS Surpr.
-27.5%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.59
EPS Est.
-$0.67
EPS Surpr.
+11.9%
Revenue
$0.01B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.58
EPS Surpr.
+8.6%
Revenue
$0.01B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.55
EPS Surpr.
+3.6%
Revenue
—
Q1 FY2025
Mar 19, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.42
EPS Surpr.
-9.5%
Revenue
—
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.38
EPS Est.
-$0.47
EPS Surpr.
+19.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.88 | $-0.62 | $-0.25 | 2 |
| Q3 FY2028 | $-1.23 | $-0.87 | $-0.35 | 2 |
| Q2 FY2028 | $-1.34 | $-0.95 | $-0.39 | 2 |
| Q1 FY2028 | $-1.49 | $-1.05 | $-0.43 | 2 |
| Q4 FY2027 | $-1.69 | $-1.20 | $-0.49 | 1 |
| Q3 FY2027 | $-1.75 | $-1.24 | $-0.51 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.1B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -20.0% | $10.06 | $9.99 | -0.70% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -27.5% | $11.00 | $9.03 | -17.91% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +11.9% | $28.05 | $21.47 | -23.46% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +8.6% | $31.67 | $30.76 | -2.87% |
| ▲ Q2 FY2025 | May 7, 2025 | +3.6% | $25.89 | $25.34 | -2.12% |
| ▼ Q1 FY2025 | Mar 19, 2025 | -9.5% | $24.40 | $25.52 | +4.59% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +19.1% | $28.65 | $32.23 | +12.50% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +18.4% | $23.17 | $23.50 | +1.42% |
Q2 FY2026-0.70%
Report Date
May 11, 2026
EPS Beat/Miss
-20.0%
Price Before
$10.06
Price After
$9.99
Q1 FY2026-17.91%
Report Date
Mar 24, 2026
EPS Beat/Miss
-27.5%
Price Before
$11.00
Price After
$9.03
Q4 FY2025-23.46%
Report Date
Nov 5, 2025
EPS Beat/Miss
+11.9%
Price Before
$28.05
Price After
$21.47
Q3 FY2025-2.87%
Report Date
Jul 30, 2025
EPS Beat/Miss
+8.6%
Price Before
$31.67
Price After
$30.76
Q2 FY2025-2.12%
Report Date
May 7, 2025
EPS Beat/Miss
+3.6%
Price Before
$25.89
Price After
$25.34
Q1 FY2025+4.59%
Report Date
Mar 19, 2025
EPS Beat/Miss
-9.5%
Price Before
$24.40
Price After
$25.52
Q4 FY2024+12.50%
Report Date
Nov 6, 2024
EPS Beat/Miss
+19.1%
Price Before
$28.65
Price After
$32.23
Q3 FY2024+1.42%
Report Date
Aug 14, 2024
EPS Beat/Miss
+18.4%
Price Before
$23.17
Price After
$23.50
Avg Beat Reaction-2.91%
Avg Miss Reaction-4.67%
Beat Rate5 / 8 quarters
Largest Move-23.46% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LENZ ends December
LENZ Therapeutics, Inc. (LENZ) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-1.32 — missing the analyst consensus of $-1.10 by -20.0%. The next LENZ earnings date is expected around September 1, 2026.
Each quarter, investors track LENZ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LENZ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LENZ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LENZ earnings · 5 questionsLENZ Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. LENZ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LENZ historically reports after market close (AMC).
LENZ earnings datewhen is LENZ earningsLENZ next earnings datewhen does LENZ report earningsLENZ earnings calendar
▸ Source: FMP · LENZ Therapeutics, Inc. SEC filings · US GAAP · LENZ Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026